RASi associated with reduced risk of KRT compared with CCB in CKD patients

November 24, 2020

RASi Associated With Reduced Risk of Kidney Replacement Therapy Compared With CCB in Patients With Advanced CKD

There is uncertainty regarding the best antihypertensive medications to use in patients with CKD G4-5 as they are often excluded from clinical trials. In a population-based Swedish database, researchers studied the clinical outcomes of starting renin-angiotensin system inhibitor (RASi) or calcium channel blockers (CCB) in 2,458 patients with CKD G4-5. Compared with CCB, RASi initiation was associated with a lower risk of KRT, but similar risks of mortality and major adverse cardiovascular events. These findings suggest that RASi initiation might slow the progression of kidney disease compared with CCB in patients with advanced CKD, and offer similar cardiovascular protection.
-end-
ARTICLE TITLE: Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study

AUTHORS: Edouard L. Fu, BSc, Catherine M. Clase, MB MSc, Marie Evans, MD, PhD, Bengt Lindholm, MD, PhD, Joris I. Rotmans, MD, PhD, Friedo W. Dekker, PhD, Merel van Diepen, PhD, Juan-Jesus Carrero, PharmD, PhD

DOI: https://doi.org/10.1053/j.ajkd.2020.10.006

National Kidney Foundation

Related Progression Articles from Brightsurf:

How hormone therapy slows progression of atherosclerosis
As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health benefits, including slowing the progression of atherosclerosis.

Discovery could help slow down progression of Parkinson's disease
A collaboration between scientists at Rutgers University and Scripps Research leads to the discovery of a small molecule that may slow down or stop the progression of Parkinson's disease

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

Apathy as an indicator of progression in Huntington's disease
IDIBELL-UB researchers associate changes in white matter connectivity in different subtypes of apathy, one of the most common psychiatric syndromes in Huntington's disease (HD).

Study maps genetics of early progression in TB
Study identifies possible gene variants that determine whether a person infected with TB will progress rapidly to active disease.

Describing aspects of melanoma progression
Three related articles and an editorial focus on various aspects of melanoma progression.

High-strength MRI tracks MS progression
The development of scars, or lesions, in the brain's cortical gray matter is a powerful predictor of neurological disability for people with multiple sclerosis (MS), according to new study.

Early prediction of Alzheimer's progression in blood
Scientists at the German Center for Neurodegenerative Diseases, the Hertie Institute for Clinical Brain Research and the University Hospital Tuebingen show that a protein found in the blood can be used to precisely monitor disease progression of Alzheimer's long before first clinical signs appear.

Function of neutrophils during tumor progression unraveled
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and facilitate tumor cell seeding and establishment of metastasis.

Glycans at the 'I' of the storm in humoral immunity and melanoma progression
Two new studies have unveiled how a peculiar molecule impacts how antibody-producing cells develop and function as well as how normal melanocytes progress to melanoma malignancy.

Read More: Progression News and Progression Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.